首页> 中文期刊> 《中国继续医学教育》 >西地那非联合依帕司他治疗2型糖尿病勃起功能障碍疗效观察及安全性评价

西地那非联合依帕司他治疗2型糖尿病勃起功能障碍疗效观察及安全性评价

             

摘要

目的:探讨分析西地那非联合依帕司他治疗2型糖尿病勃起功能障碍疗效观察及安全性。方法选取我院2013年7月~2014年7月收治的112例2型糖尿病勃起功能障碍患者,将其分为观察组(56例)和对照组(56例),给予观察组患者西地那非联合依帕司他治疗,给予对照组患者单纯西地那非治疗。对比两组患者IIEF-5、EQS评分值及不良反应。结果经治疗,两组IIEF-5、EQS均分值都优于治疗前(P<0.05),其中观察组评分优于对照组,差异对比有意义(P<0.05)。结论西地那非联合依帕司他治疗2型糖尿病勃起功能障碍效果显著,能有效的改善患者病情,安全性较高,值得临床推广和应用。%Objective To investigate the analysis of sildenafil combined with epalrestat in treatment of type 2 diabetic patients with erectile dysfunction, efifcacy and safety. Methods 112 patients with type 2 diabetes mellitus erectile dysfunction were selected in our hospital in 2013 July~2014 year in July were, divided into observation group (56 cases) and control group (56 cases), the patients in observation group were given sildenafil combined with epalrestat treatment given to the control group, patients with simple western the non treatment.Compared two groups of patients with IIEF-5, EQS score and adverse reaction. Results Aftertreatment, two groups of IIEF-5, EQS were scores are better than before treatment (P<0.05), the observation group was superior to the control group, the differencecompared with significance (P<0.05). Conclusion Sildenafil and epalrestat in treatment oftype 2 diabetes mellitus erectile dysfunction and obvious effect, can effectivelyimprove the patient's condition, high security, is worth the clinical promotion and application.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号